Skip to main content

Aleph Farms

ApplicationRehovot, IsraelFounded 2017· One of 381 Application companies tracked by AMPulse

Develops cultivated beef steaks using 3D bioprinting and cellular agriculture technology, producing slaughter-free meat with the taste, texture, and structure of conventional steak.

CEO / Founder
Didier Toubia
Team Size
51-200
Stage
Active
Total Funding
$163M
Key Investors
L Catterton; DisruptAD; Cargill; Strauss Group; VisVires New Protein; Peregrine Ventures; CPT Capital

Technology & Products

Key Products

Cultivated beef steaks (Aleph Cuts™) produced using 3D bioprinting and cellular agriculture technology. Also utilizes AI for production efficiency.

Technological Advantage

Patented bioprinting process for creating textured meat without antibiotics or serum, protected by intellectual property; first company to achieve regulatory approval for cultivated beef in Israel.

Differentiation

Value Proposition

Reduces environmental impact by cutting greenhouse gas emissions by up to 96%, land use by 99%, and water use by 96% compared to conventional beef production, while offering a humane, slaughter-free product with regulatory approval.

How They Differentiate

Focuses on whole-cut beef steaks using 3D bioprinting for structured texture, unlike competitors producing ground meat or chicken; achieved first regulatory approval for cultivated beef, with a proprietary scalable platform reducing production steps and costs.

Market & Competition

Target Customers

Premium beef consumers, food retailers, and restaurants seeking sustainable and ethical meat alternatives.

Industry Verticals

Food and Beverage; Cellular Agriculture; Alternative Protein

Competitors

Meatable, SuperMeat, Mosa Meat

Growth & Milestones

Growth Metrics

Raised $105M in Series B (2021) and $29M in recent funding (2025); employee count estimated at 150+ as of 2023.

Major Milestones

Founded in 2017; First cultivated thin-cut steak in 2018; First cultivated ribeye steak in 2021; Regulatory approval for cultivated beef in Israel in 2023; Partnership with The Cultured Hub for commercial production set for 2026

Notable Customers

Chef Marcus Samuelsson; Miznon Chef Eyal Shani; Thai Union; CJ CheilJedang

https://www.aleph-farms.com

Why this company matters

Aleph Farms occupies a distinct niche in the alternative protein market by focusing on whole-cut beef steaks rather than ground meat or chicken. Most cultivated meat companies produce unstructured products; Aleph Farms uses a proprietary 3D tissue engineering platform called BioFarm that mimics natural muscle regeneration, enabling the creation of steaks with layered muscle and fat cells. This approach targets premium consumers and food service operators seeking a product that matches the sensory experience of conventional steak.

The core technology combines bioprinting (material extrusion) with cellular agriculture. Bovine cells are printed into structured layers that develop into muscle and fat tissue without antibiotics or serum. The company also integrates AI to optimize production efficiency. Its first product, Aleph Cuts™, received regulatory approval in Israel in 2023, making it the first cultivated beef approved anywhere. A partnership with The Cultured Hub — backed by Migros, Givaudan, and Bühler Group — targets commercial production by 2026.

Customers include high-profile chefs such as Marcus Samuelsson and Eyal Shani, as well as strategic partners Thai Union and CJ CheilJedang. The company has raised $163 million from investors including L Catterton, Cargill, and DisruptAD. Competitors like Mosa Meat, Meatable, and SuperMeat focus primarily on ground meat or chicken, leaving Aleph Farms as the leading pure-play whole-cut beef producer using bioprinting.

The key strategic question is whether the BioFarm platform can achieve cost parity with premium beef at commercial scale. While the company claims a 96% reduction in greenhouse gas emissions and land use versus conventional beef, the capital intensity of bioprinting and cell culture remains high. Regulatory approvals beyond Israel and the 2026 production launch will be critical milestones for validating the technology's scalability.